Aldeyra Q3 2022 Earnings Report
Key Takeaways
Aldeyra Therapeutics reported a net loss of $14.6 million for the third quarter of 2022, with cash, cash equivalents, and marketable securities exceeding $185.3 million as of September 30, 2022. The company is progressing with NDA submissions for reproxalap and ADX-2191 and advancing its pipeline of therapies for immune-mediated diseases.
NDA submission of Reproxalap for dry eye disease is on schedule for Q4 2022.
Pre-NDA meeting with the FDA is scheduled for Q4 2022 to discuss NDA submission of ADX-2191 for primary vitreoretinal lymphoma.
Top-line results from the Phase 2 clinical trial of oral RASP modulator ADX-629 in acute alcoholic hepatitis are expected by the end of 2022.
Cash, cash equivalents, and marketable securities exceeded $185.3 million as of September 30, 2022.
Aldeyra
Aldeyra
Forward Guidance
Aldeyra believes that existing cash, cash equivalents, and marketable securities will be sufficient to fund currently projected operating expenses through the end of 2023, including NDA submissions and initial commercialization of reproxalap and ADX-2191, if approved; and continued early and late-stage development of Aldeyra’s product candidates in ocular and systemic immune-mediated diseases.
Positive Outlook
- NDA submissions for reproxalap and ADX-2191
- Potential initial commercialization of reproxalap and ADX-2191, if approved
- Continued early-stage development of Aldeyra’s product candidates
- Continued late-stage development of Aldeyra’s product candidates
- Sufficient funds to cover operating expenses through the end of 2023